Swedish Orphan Biovitrum Gains EU Approval for Aspaveli, Boosts 2025 Outlook
Swedish Orphan Biovitrum’s Aspaveli gains EU approval, boosting sales guidance and brokerage upside as the company expands its rare‑kidney drug portfolio.
3 minutes to read